Key result
Remdesivir is linked to reversible asymptomatic bradycardia in COVID-19.
Why the study?
The cardiac effects of remdesivir in COVID-19 patients are rarely reported despite its common use and known side effects.
Does intravenous remdesivir cause bradycardia in patients with COVID-19?
Case Report (n=1)
No
Does intravenous remdesivir cause bradycardia in patients with COVID-19?
Answers are grounded in this paper and cite their sources.
Remdesivir treatment for COVID-19 may be associated with significant bradycardia, warranting careful electrocardiographic monitoring.
Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported. A 44-year-old woman with symptomatic confirmed COVID-19 was treated with intravenous remdesivir 200 mg on day one and followed with 100 mg remdesivir until day five. Three days after the treatment, she had significant bradycardia shown on the electrocardiography; however, the patient had no complaint or symptom regarding the bradycardia. Based on the discussion with the cardiology team, it was decided to cease remdesivir and replace it with oseltamivir, and the ECG showed some improvement. Remdesivir is a drug that should be used safely and cannot be taken at home, as there may be side effects left unaware.
No takes yet. Share an insight, caveat, or question.
Purwowiyoto et al. (2022) conducted a case report in COVID-19 (n=1). Remdesivir was evaluated on Development of bradycardia. Administration of remdesivir in a 44-year-old woman with COVID-19 was associated with the development of significant asymptomatic bradycardia that resolved upon discontinuation of the drug.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: